Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Clinical trial NCT02604511 · COMPLETED
Trial details
- NCT number
- NCT02604511
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2022-11-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.